StockStory.org on MSN

MRNA Q3 Deep Dive: Cost Controls and Pipeline Progress Amid Declining COVID Vaccine Demand

Biotechnology company Moderna (NASDAQ:MRNA) reported in Q3 CY2025, but sales fell by 45.4% year on year to $1.02 billion. On ...
News-Medical.Net

BIOVECTRA and Revolution Biomanufacturing partner to deliver integrated mRNA Design and GMP production services

BIOVECTRA, a part of Agilent Technologies Inc., and Revolution Biomanufacturing Inc. today announced a collaboration that ...